EUVIMEDEUVIMED entdecken
Crossref

Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9

Hyun Hwan Hwang, Ki Ho Chang, Yi Young Choi, Ii-Du Jung, In-Cheol Kang, Youngjin Choi, Mi Jin O, Chang-Keun Cho, Pureum Kang, Hye-Jung Park, Choon-Gon Jang, Seok-Yong Lee

Drug Targets and Therapeutics · 2022

DOI: 10.58502/dtt.22.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Targets and Therapeutics, 2022. Verfasst von Hyun Hwan Hwang und 11 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Hwang, H. H., Chang, K. H., Choi, Y. Y., Jung, I., Kang, I., Choi, Y., O, M. J., Cho, C., Kang, P., Park, H., Jang, C., & Lee, S. (2022). Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9. Drug Targets and Therapeutics. https://doi.org/10.58502/dtt.22.003

Vancouver

Hwang HH, Chang KH, Choi YY, Jung I, Kang I, Choi Y, et al. Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9. Drug Targets and Therapeutics. 2022. doi:10.58502/dtt.22.003

BibTeX
@article{Hwang2022,
  author = {Hwang, Hyun Hwan and Chang, Ki Ho and Choi, Yi Young and Jung, Ii-Du and Kang, In-Cheol and Choi, Youngjin and O, Mi Jin and Cho, Chang-Keun and Kang, Pureum and Park, Hye-Jung and Jang, Choon-Gon and Lee, Seok-Yong},
  title = {Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9},
  journal = {Drug Targets and Therapeutics},
  year = {2022},
  doi = {10.58502/dtt.22.003}
}
Kostenlos starten →